Free tool
FAERS Monitor: Arnuity Ellipta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205625 or its brand name (Arnuity Ellipta, Fluticasone Furoate). Reports on generic versions are filed under their own applications.
Reports
9,896
Serious
6,929
70% of reports
Hospitalization
2,819
Death reported
616
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea1,572
- drug ineffective1,570
- asthma1,315
- off label use926
- cough911
- wheezing908
- therapeutic product effect incomplete766
- nausea686
- pain665
- pneumonia661
- macular degeneration632
- malaise620
- headache600
- vomiting584
- fatigue561
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 4 |
| 2009 | 3 |
| 2010 | 17 |
| 2011 | 52 |
| 2012 | 266 |
| 2013 | 43 |
| 2014 | 76 |
| 2015 | 156 |
| 2016 | 219 |
| 2017 | 423 |
| 2018 | 583 |
| 2019 | 690 |
| 2020 | 852 |
| 2021 | 1,246 |
| 2022 | 1,096 |
| 2023 | 1,134 |
| 2024 | 1,145 |
| 2025 | 1,105 |
| 2026 | 785 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,263 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| macular degenerationSignal | 632 | 118.7 | 109.8 | 69,779 |
| wheezingSignal | 908 | 33.0 | 31.0 | 27,821 |
| asthmaSignal | 1,315 | 25.0 | 23.8 | 30,096 |
| therapeutic product effect incompleteSignal | 766 | 23.1 | 21.6 | 16,072 |
| coughSignal | 911 | 6.9 | 6.5 | 4,658 |
| dyspnoeaSignal | 1,572 | 5.9 | 5.7 | 6,576 |
| pneumoniaSignal | 661 | 4.3 | 4.0 | 1,723 |
| malaiseSignal | 620 | 3.0 | 2.8 | 845 |
| vomitingSignal | 584 | 2.6 | 2.4 | 607 |
| drug ineffectiveSignal | 1,570 | 2.5 | 2.4 | 1,552 |
| painSignal | 665 | 2.3 | 2.1 | 503 |
| off label useSignal | 926 | 2.2 | 2.1 | 668 |
| headacheSignal | 600 | 2.0 | 1.9 | 324 |
| nausea | 686 | 1.8 | 1.7 | 274 |
| fatigue | 561 | 1.5 | 1.4 | 107 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.